ClinicalTrials.gg
CompletedNCT04524221Updated May 23, 2022

PTG-100 for Patients With Celiac Disease

A Phase 1 interventional study of PTG-100 and Placebo in Celiac Disease, sponsored by Nielsen Fernandez-Becker. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-05-23.

Sponsored by Nielsen Fernandez-Becker · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Apr 2022, 4 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 103 studies in Celiac Disease with a site in United States — 16 open to participants now, 20 under way, none of them phase 3. Celiac Disease · United States.

Enrollment
58th of 68
12 · median 46
Started
2021
with 3 others
Phase 1
16 of 103
1 open now
Registered
72nd of 103
by date

Among the 103 studies in Celiac Disease with a site in United States, this one is the 58th largest by enrollment of the 68 interventional ones that give a count, is one of 4 that started in 2021, is one of 16 in phase 1, and was the 72nd registered.

Celiac Disease

353 studies on the registry are indexed under Celiac Disease; 78 are open to participants now.

Browse Celiac Disease studies →

Open to participants now

16 of the 103 studies in Celiac Disease with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 48 Celiac Disease studies recruiting now, 24 (50%) set no upper age limit and 19 (40%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Celiac Disease with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to learn whether or not the drug PTG-100 can reduce or prevent inflammatory injury to the small intestine that occurs when people with celiac disease eat food products containing gluten.

This is a clinical research study to determine the safety and efficacy of PTG-100 in preventing gluten-induced inflammatory injury to the small intestine in patients with celiac disease. 30 patients will receive either placebo (fake drug) or PTG-100 (real drug) in capsule form twice daily for 42 days. They will also receive a gluten challenge twice daily in the form of a cookie or equivalent. An upper gastrointestinal endoscopy and exam including small bowel mucosa biopsy will be performed at the start of the treatment period and again at the end. Blood samples will be routinely taken to evaluate safety and the drug's mechanism of action throughout the study, and symptoms will be recorded using the celiac symptoms index (CSI) survey.

03

Conditions studied

  • Celiac Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of celiac disease

Exclusion criteria

Exclusion Criteria:

  • Active GI disease or history of diseases
  • Diagnosis of Crohn's disease or ulcerative colitis.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    PTG-100

    Patients will receive either placebo (fake drug) or PTG-100 (real drug) in capsule form twice daily for 42 days.

    Drug: PTG-100

  • Placebo comparator
    Placebo

    Patients will receive either placebo (fake drug) or PTG-100 (real drug) in capsule form twice daily for 42 days.

    Drug: Placebo

Interventions

  • DrugPTG-100

    PTG-100, 600mg taken twice daily in capsule form for 42 days

  • DrugPlacebo

    Placebo taken twice daily in capsule form for 42 days

06

What researchers measure

Primary outcomes

  1. Percentage change in villous height-to crypt ratio

    Percentage change from baseline to Week 6 in villous height-to crypt depth (Vh:Cd) ratio

    Time frame: 42 days

Secondary outcomes

  1. Change in celiac disease antibodies

    Changes in anti-tTG antibodies from baseline

    Time frame: 42 days

  2. Changes in celiac disease antibodies

    Changes in anti-DGP antibodies from baseline

    Time frame: 42 days

  3. CD3- positive intraepithelial lymphocyte density

    CD3- positive intraepithelial lymphocyte density

    Time frame: 42 days

  4. Celiac symptom index (CSI)

    Changes in validated celiac symptom index (CSI)

    Time frame: 42 days

  5. Characterization of immune modulators underlying mechanism of action in celiac disease.

    Identification of immune cell populations targeted by PTG-100 to better understand mechanism of action in celiac disease in both blood and tissue temporally following exposure to drug.

    Time frame: 42 days

07

Study locations

1 site
  • Stanford University
    Redwood City, California 94063, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Apr 2022, 13 months.

Of 14 phase 1 interventional studies under Celiac Disease, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 13 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2020
First posted
Aug 24, 2020
StartActual
Feb 26, 2021
Primary completionActual
Apr 3, 2022
CompletionActual
Apr 3, 2022
Last update
May 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04524221
Lead sponsor
Nielsen Fernandez-Becker
Collaborators
Protagonist Therapeutics, Inc.
Responsible party
Nielsen Fernandez-Becker (Clinical Associate Professor, Medicine, Stanford University) — Sponsor-investigator
First posted
Aug 24, 2020
Start date
Feb 26, 2021
Primary completion
Apr 3, 2022
Completion
Apr 3, 2022
Last update
May 23, 2022

Study contacts

Nielsen Q Fernandez-Becker, MD, PhD
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion